Chiesi’s Elfabrio receives NICE recommendation
The therapy has been developed for the treatment of Fabry disease among adult patients
Read More
Tag: elfabrio
Elfabrio receives vital MHRA authorisation
The therapy involves long-term enzyme replacement therapy for aduls with Fabry disease
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
